Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Cidara Therapeutics, Inc. (CDTX)

0.6701   -0.06 (-8.18%) 09-24 15:06
Open: 0.7178 Pre. Close: 0.7298
High: 0.726 Low: 0.655
Volume: 286,109 Market Cap: 47(M)
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.73 - 0.73 0.73 - 0.74
Low: 0.64 - 0.65 0.65 - 0.65
Close: 0.66 - 0.67 0.67 - 0.68

Technical analysis

as of: 2022-09-23 4:22:55 PM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 0.86     One year: 0.94
Support: Support1: 0.63    Support2: 0.52
Resistance: Resistance1: 0.73    Resistance2: 0.8
Pivot: 0.71
Moving Average: MA(5): 0.74     MA(20): 0.71
MA(100): 0.61     MA(250): 0.92
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 52     %D(3): 67
RSI: RSI(14): 43.5
52-week: High: 2.2  Low: 0.4
Average Vol(K): 3-Month: 508 (K)  10-Days: 228 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CDTX ] has closed above bottom band by 20.5%. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 21 Sep 2022
Thinking about buying stock in AgriFORCE Growing Systems, Cidara Therapeutics, Palantir Technologies, Applied Optoelectronics, or Earthstone Energy? - PR Newswire

Tue, 20 Sep 2022
Cidara Therapeutics (CDTX) Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis - StreetInsider.com

Tue, 13 Sep 2022
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of Influenza - Yahoo Finance

Tue, 09 Aug 2022
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results - Yahoo Finance

Mon, 01 Aug 2022
Short Volatility Alert: Cidara Therapeutics, Inc. - Cidara Therapeutics (NASDAQ:CDTX) - Benzinga

Mon, 01 Aug 2022
Investors in Cidara Therapeutics (NASDAQ:CDTX) from five years ago are still down 88%, even after 14% gain this past week - Simply Wall St

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 70 (M)
% Held by Insiders 4.614e+007 (%)
% Held by Institutions 11.6 (%)
Shares Short 463 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -6.602e+007
EPS Est Next Qtl -0.88
EPS Est This Year -3.61
EPS Est Next Year -3.29
Book Value (p.s.) 0
Profit Margin (%) -240
Operating Margin (%) -239.6
Return on Assets (ttm) -80.2
Return on Equity (ttm) -1
Qtrly Rev. Growth 2.763e+007
Gross Profit (p.s.) -53.01
Sales Per Share 453.3
EBITDA (p.s.) -1.53725e+007
Qtrly Earnings Growth -0.8
Operating Cash Flow 0 (M)
Levered Free Cash Flow -62 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales 0
Price to Cash Flow -8.55

Stock Dividends

Dividend 0
Forward Dividend 853460
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.